Unicycive Therapeutics Reports $14.5 Million Net Loss and Increased Operating Expenses for First Half of 2026

Unicycive Therapeutics, Inc. reported its financial results for the six months ending June 30, 2026, revealing a net loss of $14.5 million, a significant increase from a loss of $5.9 million during the same period in 2025. The company's total operating expenses rose to $18.6 million, up 24% from $15 million in the prior year, driven primarily by increased research and development costs, which grew by 12% to $4.4 million, and general and administrative expenses, which increased by 29% to $14.2 million. The company attributed these increases to higher non-cash stock-based compensation and costs associated with preparing for the commercial launch of its products.

In terms of liquidity, Unicycive reported cash and cash equivalents of $44.2 million as of June 30, 2026, a notable increase from $29.2 million at the end of 2025. The company generated $34 million in net cash from financing activities during the first half of 2026, primarily through the sale of common stock under a sales agreement with Guggenheim Securities. This influx of capital is expected to support ongoing clinical trials and operational expenses as the company continues to develop its product candidates, including oxylanthanum carbonate and UNI-494.

Operationally, Unicycive has made significant strides in its product development pipeline. The company is focused on oxylanthanum carbonate, a treatment for hyperphosphatemia in chronic kidney disease patients, and UNI-494, aimed at treating acute kidney injury. The company has completed a Phase I clinical study for UNI-494 and is preparing for further clinical trials. However, it faced a setback when the FDA issued a Complete Response Letter (CRL) regarding its New Drug Application (NDA) for oxylanthanum carbonate, citing manufacturing deficiencies. The company has since resubmitted its NDA and is awaiting further feedback from the FDA.

Unicycive's employee headcount has also increased as the company expands its operational capabilities to support its clinical and commercial objectives. The company continues to evaluate additional technologies and drugs for potential licensing to enhance its product portfolio. Looking ahead, Unicycive anticipates that it will need to raise additional capital to fund its ongoing development efforts and is exploring various financing options, including equity offerings and collaborations. The company remains optimistic about its ability to secure the necessary funding to continue its operations and advance its product candidates through the regulatory process.